Feeds:
Posts
Comments

Posts Tagged ‘Bausch & Lomb’

*****

TODAY’S NEWS

AstraZeneca still waiting for the upside of MedImmune acquisition.

Pfizer: More Lipitor, fewer heart complications – A reanalysis of research data found a high dose of popular cholesterol pill Lipitor lowers risk of heart attack and stroke in some patients with both heart disease and kidney disease, the drug’s maker said Mondaymore

Fred Hassan heads to Bausch & Lomb.

Novartis‘ Tekturna post-heart attack: Not a good idea. “Given these results, we are not currently recommending the use of this agent in addition to other inhibitors of the renin-angiotensin system in this specific patient population.”

Access to docs flat, but appointments on the rise.

RECOMMENDED

eLearning Development – From modules to virtual preceptorships to virtual worlds, we’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

“I hate her uterus!” DTC, infertility, and a very effective on-line campaign. IncreaseYourChances.

JUST FOR FUN

Human, squirrel, or anvil? A great Dilbert cartoon today!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

Teva‘s Copaxone approved for preventative treament of MS – The drug is already approved to treat relapsing-remitting multiple sclerosis, where new symptoms occur suddenly or older symptoms become worse. The expanded approval allows for the drug’s use in people who have experienced a first episode of multiple sclerosis and have magnetic resonance imaging results consistent with the condition.

Pfizer and Bausch & Lomb in co-promote agreement for eyecare productsPfizer Inc and Bausch & Lomb announced today a co-promotion agreement involving both companies’ prescription ophthalmic pharmaceuticals in the United States. The agreement will allow both companies to greatly increase the level of eye care industry support for these important medications that treat serious ophthalmic conditions.

Vertex makes a strategic acquisition to boost pipeline. And, Bristol does some shuffling at the top.

PLUS – life after pharmaceutical sales. Dog washing. Endurance Sports. I’m betting that there are a lot more entrepreneurs among those downsized from pharma…

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Reblog this post [with Zemanta]

Read Full Post »